Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding(New York Blood Center), Anthony H. Goldstone(Royal London Hospital), Andrew McMillan(Nottingham University Hospitals NHS Trust), Hillard M. Lazarus(University Hospitals of Cleveland), Georgina Buck(MRC Clinical Trials Unit at UCL), Jacob M. Rowe(Technion – Israel Institute of Technology), Mark R. Litzow(Mayo Clinic in Arizona), Susan Richards(MRC Clinical Trials Unit at UCL), Rajesh Chopra(Vardhman Mahavir Medical College & Safdarjung Hospital), Ian Durrant(MRC Clinical Trials Unit at UCL), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), David I. Marks(University Hospitals Bristol NHS Foundation Trust), Selina M. Luger(University of Pennsylvania)
Cited by 843
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k